Insulet price to free cash flow PODD

Market value divided by free cash flow over the last twelve months, since 2023.

Today, Oct 23, 2026: 35.2×
3-year median: 73.2×
Against its 3-year history: 15th; percentile: 0 is its lowest day, 100 its highest
3-year range: 24.2× to 474×
Peer median: 18.5×

Insulet's price to free cash flow is 35.2× as of Oct 23, 2026.

That is below its 3-year median of 73.2×, lower than on 85% of days in the last 3 years.

Over that time it ranged from 24.2× in May 2026 to 474× in Aug 2023.

The median for 10 medical instruments and supplies stocks of a similar size is 18.5×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	35.2×	24.2×	48.0×
2025	47.9×	47.9×	87.4×
2024	81.9×	66.8×	353×
2023	374×	267×	474×

Against its peers

Companies in Medical - Instruments & Supplies nearest Insulet's size, closest first, today.

Company	Price to free cash flow
PODDInsulet	35.2×
GMEDGlobus Medical	14.5×
ALGNAlign Technology	17.3×
COOCooper Companies	17.2×
PENPenumbra	59.2×
SOLVSolventum	n/m
MSAMSA Safety	19.8×
MMSIMerit Medical Systems	27.4×
HAEHaemonetics	18.5×
VNTVontier	12.1×
BMIBadger Meter	29.2×
Peer median	18.5×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Insulet

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.